

# Contents

*List of contributors* vii

*Acknowledgments* xi

---

## Section I: The Pharmacological Basis for Parkinson's Disease Treatment

- 1 **The pharmacological basis of Parkinson's disease therapy: an overview** 1  
Néstor Gálvez-Jiménez, Hubert H. Fernandez, Alberto J. Espay and Susan H. Fox
- 2 **Anticholinergic agents in the management of Parkinson's disease** 5  
Juan Carlos Giugni and Ramon L. Rodriguez-Cruz
- 3 **Amantadine and antiglutamatergic drugs in the management of Parkinson's disease** 13  
Marco Onofri, Valerio Frazzini, Laura Bonanni and Astrid Thomas
- 4 **Monoamine oxidase inhibitors in the management of Parkinson's disease** 23  
Sven-Eric Pålhagen
- 5 **Oral dopamine agonists in the management of Parkinson's disease** 34  
Javier Pagonabarraga, Juan Marín-Lahoz and Jaime Kulisevsky
- 6 **Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson's disease** 48  
Antoniya Todorova and K. Ray Chaudhuri
- 7 **Oral and infusion levodopa therapy in the management of Parkinson's disease** 63  
M. Angela Cenci-Nilsson and Per Odin
- 8 **Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease** 76  
Ilana Schlesinger and Amos D. Korczyn

- 9 **Experimental pharmacological agents in the management of Parkinson's disease** 83  
Krishe Menezes, Lawrence W. Elmer and Robert A. Hauser

## Section II: Management of Nonmotor Symptoms of Parkinson's Disease

- 10 **Management of autonomic dysfunction in Parkinson's disease** 93  
Shen-Yang Lim and Ai Huey Tan
- 11 **Management of cognitive impairment in Parkinson's disease** 111  
Dawn M. Schiehser, Eva Pirogovsky-Turk and Irene Litvan
- 12 **A neurobehavioralist approach to the management of cognitive impairment in Parkinson's disease** 122  
Po-Heng Tsai
- 13 **Management of disease-related behavioral disturbances in Parkinson's disease** 127  
Joseph H. Friedman
- 14 **Management of treatment-related behavioral disturbances in Parkinson's disease** 139  
Mayur Pandya, Dimitrios A. Nacopoulos and Naveed Khokhar
- 15 **Management of sleep disorders in Parkinson's disease** 151  
Daniela Calandrella and Alberto Albanese
- 16 **Management of pain and neuromuscular complications in Parkinson's disease** 162  
John A. Morren

## Contents

## Section III: Surgical Management of Parkinson's Disease

- 17 **Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease** 175  
Malco Rossi, Daniel Cerquetti, Jorge Mandolesi and Marcelo Merello
- 18 **Deep-brain stimulation of the globus pallidus internus in the management of Parkinson's disease** 187  
Lilia C. Lovera, Alberto J. Espay and Andrew P. Duker
- 19 **Deep-brain stimulation of the subthalamic nucleus in the management of Parkinson's disease** 195  
David A. Schmerler, Alberto J. Espay and Andrew P. Duker
- 20 **Deep-brain stimulation of the thalamic ventral intermediate nucleus in the management of Parkinson's disease** 206  
Diana Apetauerova, Jay L. Shils and Peter K. DEMPSEY
- 21 **Emerging targets and other stimulation-related procedures in the management of Parkinson's disease** 216  
Tiago A. Mestre and Elena Moro
- 22 **Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease** 231  
Pablo Martinez-Martin and Carmen Rodríguez-Blázquez
- 23 **Functional imaging markers as outcome measures in clinical trials for Parkinson's disease** 242  
Ryan R. Walsh
- 24 **Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease** 249  
Thomas F. Tropea and Claire Henchcliffe
- 25 **Lessons learned: neuroprotective trials in Parkinson's disease** 265  
Isabelle Beaulieu-Boire and Anthony E. Lang
- 26 **Lessons learned: symptomatic trials in early Parkinson's disease** 280  
Ramon Lugo-Sanchez and Néstor Gálvez-Jiménez
- 27 **Controversy: globus pallidus internus versus subthalamic nucleus deep-brain stimulation in the management of Parkinson's disease** 287  
Sarah K. Bourne, Sean J. Nagel and Darlene A. Lobel
- 28 **Controversy: ablative surgery vs deep-brain stimulation in the management of Parkinson's disease** 297  
Gian D. Pal and Leo Verhagen Metman
- 29 **Controversy: midstage vs advanced-stage deep-brain stimulation in the management of Parkinson's disease** 313  
Mallory L. Hacker and David Charles
- 30 **Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease** 325  
Daniel Weintraub and Lama M. Chahine
- 31 **Lessons and challenges of trials for other nonmotor complications of Parkinson's disease** 337  
Federico E. Micheli and Carlos Zúñiga-Ramírez
- 32 **Lessons and challenges of trials involving ancillary therapies for the management of Parkinson's disease** 349  
Chris J. Hass, Elizabeth L. Stegemöller, Madeleine E. Hackney and Joe R. Nocera

---

*Index* 361

*Color plate section between pp. 324 and 325*